Cargando…

Targeted inhibition of glutamine metabolism enhances the antitumor effect of selumetinib in KRAS-mutant NSCLC

Regulated by the tumor microenvironment, the metabolic network of the tumor is reprogrammed, driven by oncogenes and tumor suppressor genes. The metabolic phenotype of tumors of different driven-genes and different tissue types is extremely heterogeneous. KRAS-mutant non-small cell lung cancer (NSCL...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xia, Meng, Li, Xuena, Diao, Yao, Du, Bulin, Li, Yaming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2020
Materias:	Original article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7644669/ https://www.ncbi.nlm.nih.gov/pubmed/33137541 http://dx.doi.org/10.1016/j.tranon.2020.100920

Ejemplares similares

Effect of IDH3a on glucose uptake in lung adenocarcinoma: A pilot study based on [(18)F]FDG
por: Du, Bulin, et al.
Publicado: (2019)

PD-L1 in Lung Adenocarcinoma: Insights into the Role of (18)F-FDG PET/CT
por: Cui, Yan, et al.
Publicado: (2020)

Discordant Metabolic Response on (18)F-FDG PET/CT in Synchronous Primary Gastric Lymphoma and Gastric Adenocarcinoma
por: Hao, Wanting, et al.
Publicado: (2022)

ATAD2 expression increases [18F]Fluorodeoxyglucose uptake value in lung adenocarcinoma via AKT-GLUT1/HK2 pathway
por: Sun, Tong, et al.
Publicado: (2019)

LncRNA AP000695.2 promotes glycolysis of lung adenocarcinoma via the miR-335-3p/TEAD1 axis: The role of AP000695.2 in glycolysis of lung adenocarcinoma
por: Xu, Shuoyan, et al.
Publicado: (2023)

Inhibition of lncRNA PART1 Chemosensitizes Wild Type but Not KRAS Mutant NSCLC Cells
por: Chen, Shu-Chen, et al.
Publicado: (2020)

Positron emission tomography/computed tomography hypermetabolism of Kikuchi–Fujimoto disease mimicking malignant lymphoma: a case report and literature review
por: Wang, Shu, et al.
Publicado: (2021)

A Renal Cyst Invaded by Infiltrating Renal Cell Carcinoma With Multiple Hypermetabolic Bone Metastases as the Initial Presentation
por: Wang, Shu, et al.
Publicado: (2022)

Phenformin enhances the therapeutic effect of selumetinib in KRAS-mutant non-small cell lung cancer irrespective of LKB1 status
por: Zhang, Jun, et al.
Publicado: (2017)

The Synthesis and Evaluations of the (68)Ga-Lissamine Rhodamine B (LRB) as a New Radiotracer for Imaging Tumors by Positron Emission Tomography
por: Li, Xuena, et al.
Publicado: (2016)

MicroRNA-4458 suppresses migration and epithelial–mesenchymal transition via targeting HMGA1 in non-small-cell lung cancer cells
por: Ma, Yu, et al.
Publicado: (2019)

Fuzzy Planar Cell Polarity Gene (FUZ) Promtes Cell Glycolysis, Migration, and Invasion in Non-small Cell Lung Cancer via the Phosphoinositide 3-Kinase/Protein Kinase B Pathway
por: Wang, Shu, et al.
Publicado: (2022)

Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer
por: Jänne, P A, et al.
Publicado: (2015)

Thyroid Remnant Estimation by Diagnostic Dose (131) I Scintigraphy or (99m) T c O (4) (−) Scintigraphy after Thyroidectomy: A Comparison with Therapeutic Dose (131) I Imaging
por: Liu, Guanghui, et al.
Publicado: (2016)

Can (18)F-FDG PET/CT predict EGFR status in patients with non-small cell lung cancer? A systematic review and meta-analysis
por: Du, Bulin, et al.
Publicado: (2021)

FAPI PET/CT in Diagnostic and Treatment Management of Colorectal Cancer: Review of Current Research Status
por: Cheng, Zhiming, et al.
Publicado: (2023)

The long noncoding RNA HOXA11‐AS promotes lung adenocarcinoma proliferation and glycolysis via the microRNA‐148b‐3p/PKM2 axis
por: Chen, Wenkun, et al.
Publicado: (2022)

Highlighting Fibroblasts Activation in Fibrosis: The State-of-The-Art Fibroblast Activation Protein Inhibitor PET Imaging in Cardiovascular Diseases
por: Cui, Yan, et al.
Publicado: (2023)

Treating KRAS-mutant NSCLC: latest evidence and clinical consequences
por: Garrido, Pilar, et al.
Publicado: (2017)

Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC
por: Liu, Weiran, et al.
Publicado: (2016)

Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRAS(G12R)-mutant pancreatic ductal adenocarcinoma
por: Kenney, Cara, et al.
Publicado: (2021)

Inhibition of YAP Sensitizes the Selumetinib Treatment for Neurofibromatosis Type 1 Related Plexiform Neurofibroma
por: Tian, Zhuowei, et al.
Publicado: (2023)

Different metabolic responses to PI3K inhibition in NSCLC cells harboring wild-type and G12C mutant KRAS
por: Caiola, Elisa, et al.
Publicado: (2016)

Clinicopathologic Characteristics and Outcomes for Patients With KRAS G12D-Mutant NSCLC
por: Cooper, Alissa J., et al.
Publicado: (2022)

Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
por: Adachi, Yuta, et al.
Publicado: (2021)

A randomised phase II trial of selumetinib vs selumetinib plus temsirolimus for soft-tissue sarcomas
por: Eroglu, Z, et al.
Publicado: (2015)

A CRISPR screen identifies MAPK7 as a target for combination with MEK inhibition in KRAS mutant NSCLC
por: Dompe, Nicholas, et al.
Publicado: (2018)

Restricting Glutamine Uptake Enhances NSCLC Sensitivity to Third-Generation EGFR-TKI Almonertinib
por: Liu, Yaming, et al.
Publicado: (2021)

Identification of the Major Degradation Pathways of Selumetinib
por: Bouchema, Tahar Sif eddine, et al.
Publicado: (2022)

Glucose and glutamine metabolism in relation to mutational status in NSCLC histological subtypes
por: Meijer, Tineke W.H., et al.
Publicado: (2019)

Altered Transcriptional Control Networks with Trans-Differentiation of Isogenic Mutant-KRas NSCLC Models
por: Haley, John A., et al.
Publicado: (2014)

Neuroprotective effect of selumetinib on acrolein-induced neurotoxicity
por: Huang, Hui-Ju, et al.
Publicado: (2021)

Efficacy of immunotherapy in KRAS-mutant advanced NSCLC: A real-world study in a Chinese population
por: Peng, Lixiu, et al.
Publicado: (2023)

PTPRH promotes the progression of non-small cell lung cancer via glycolysis mediated by the PI3K/AKT/mTOR signaling pathway
por: Wang, Shu, et al.
Publicado: (2023)

Regulation of MEK inhibitor selumetinib sensitivity by AKT phosphorylation in the novel BRAF L525R mutant
por: Nakai, Chikako, et al.
Publicado: (2023)

Comparative metabolomics profiling of isogenic KRAS wild type and mutant NSCLC cells in vitro and in vivo
por: Brunelli, Laura, et al.
Publicado: (2016)

SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting
por: Greystoke, Alastair, et al.
Publicado: (2017)

Distinct metabolic preference of atypical KRAS mutant
por: Cheong, Heesun
Publicado: (2020)

Profile of selumetinib and its potential in the treatment of melanoma
por: Kim, Dae Won, et al.
Publicado: (2014)

Effect of food on capsule and granule formulations of selumetinib
por: Cohen‐Rabbie, Sarit, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_h4sp4dgc176jr364jcp4kku7s7